Abstract
INTRODUCTION: The objective of this study was to assess the effectiveness and potential benefits of the use of long-acting recombinant follicle-stimulating hormone (FSH) in a random-start protocol for fertility preservation in women with cancer.
MATERIAL AND METHODS: This is a retrospective before-and-after study performed between February 2013 and December 2015 in women who underwent ovarian hyperstimulation for oocyte cryobanking using a random-start approach. In the first part of the study period, the women were treated with daily recombinant FSH whereas in the second part the stimulation was initiated with long-acting recombinant FSH. The primary aim of the study was to compare the number of oocytes stored in the two study periods. In all, 140 women were ultimately selected.
RESULTS: Compared with daily recombinant FSH, the use of the long-acting compound was associated with a reduced number of injections (12.5 ± 3.5 vs. 16.4 ± 0.3; p < 0.001) and a longer duration of stimulation (11.4 ± 1.9 vs. 10.6 ± 1.9, p = 0.01). Conversely, the number of oocytes collected (13.7 ± 9.5 vs. 11.3 ± 7.0, p = 0.10) as well as those cryopreserved (11.0 ± 8.0 vs. 9.5 ± 5.8, p = 0.21) did not differ.
CONCLUSIONS: The use of long-acting recombinant FSH in random-start protocols for fertility preservation appears to be a valuable option.
Original language | English |
---|---|
Pages (from-to) | 949-953 |
Number of pages | 5 |
Journal | Acta Obstetricia et Gynecologica Scandinavica |
Volume | 96 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2017 |
Keywords
- Breast Neoplasms
- Delayed-Action Preparations
- Drug Administration Schedule
- Female
- Fertility Preservation
- Follicle Stimulating Hormone
- Humans
- Ovarian Neoplasms
- Ovulation Induction
- Pregnancy
- Retrospective Studies
- Treatment Outcome
- Journal Article